These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9635661)

  • 1. Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device--an alternative to protamine.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Zwischenberger JB
    Crit Care Med; 1998 Jun; 26(6):1096-102. PubMed ID: 9635661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
    ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of anticoagulation without protamine using a heparin removal device after cardiopulmonary bypass.
    Vertress RA; Zwischenberger JB; McRea JC; Tao W; Kurusz M; Conti VR
    ASAIO J; 1994; 40(3):M560-4. PubMed ID: 8555577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a heparin removal device: a prospective randomized preclinical outcomes study.
    Zwischenberger JB; Tao W; Deyo DJ; Vertrees RA; Alpard SK; Shulman G
    Ann Thorac Surg; 2001 Jan; 71(1):270-7. PubMed ID: 11216760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin clearance profiles after systemic anticoagulation using a heparin removal device system.
    Tao W; Callahan JD; Vertrees RA; Brunston RL; Deyo DJ; McRea JC; Zwischenberger JB
    ASAIO J; 1997; 43(6):922-6. PubMed ID: 9386844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant reduction in circuit pressure with modified plasma separation chamber for a heparin removal device.
    Tao W; Deyo DJ; Alpard SK; Vertrees RA; Hoang V; Zwischenberger JB
    ASAIO J; 1999; 45(1):50-2. PubMed ID: 9952007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assembly of the Heparin Removal Device for patients with suspected adverse reaction to protamine sulphate.
    Jegger D; Tevaerai HT; Horisberger J; Mueller XM; Seigneuil I; Pierrel N; Boone Y; von Segesser LK
    Perfusion; 2000 Sep; 15(5):453-6. PubMed ID: 11001169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal protamine dosing after cardiopulmonary bypass: The PRODOSE adaptive randomised controlled trial.
    Miles LF; Burt C; Arrowsmith J; McKie MA; Villar SS; Govender P; Shaylor R; Tan Z; De Silva R; Falter F
    PLoS Med; 2021 Jun; 18(6):e1003658. PubMed ID: 34097705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass.
    Mochizuki T; Olson PJ; Szlam F; Ramsay JG; Levy JH
    Anesth Analg; 1998 Oct; 87(4):781-5. PubMed ID: 9768770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation.
    Koster A; Despotis G; Gruendel M; Fischer T; Praus M; Kuppe H; Levy JH
    Anesth Analg; 2002 Jul; 95(1):26-30, table of contents. PubMed ID: 12088937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivated antithombin as anticoagulant reversal in a rat model of cardiopulmonary bypass: a potent and potentially safer alternative to protamine.
    Bianchini EP; Sebestyen A; Abache T; Bourti Y; Fontayne A; Richard V; Tamion F; Plantier JL; Doguet F; Borgel D
    Br J Haematol; 2018 Mar; 180(5):715-720. PubMed ID: 29363751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
    Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
    Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.
    Ovrum E; Brosstad F; Am Holen E; Tangen G; Abdelnoor M; Oystese R
    Eur J Cardiothorac Surg; 1996; 10(6):449-55. PubMed ID: 8817142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy.
    Feindt P; Seyfert UT; Volkmer I; Straub U; Gams E
    Thorac Cardiovasc Surg; 1994 Aug; 42(4):218-21. PubMed ID: 7529949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Point-of-Care Measurement of Kaolin Activated Clotting Time during Cardiopulmonary Bypass: A Single Sample Comparison between ACT Plus and i-STAT.
    Vranken NPA; Theelen AJAJ; Orbons T; Barenbrug PJC; Weerwind PW
    J Extra Corpor Technol; 2021 Mar; 53(1):57-61. PubMed ID: 33814607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.
    Despotis GJ; Hogue CW; Saleem R; Bigham M; Skubas N; Apostolidou I; Qayum A; Joist JH
    Anesth Analg; 2001 Jul; 93(1):28-32. PubMed ID: 11429333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged Activated Clotting Time after Protamine Administration Does Not Indicate Residual Heparinization after Cardiopulmonary Bypass in Pediatric Open Heart Surgery.
    Yamamoto T; Wolf HG; Sinzobahamvya N; Asfour B; Hraska V; Schindler E
    Thorac Cardiovasc Surg; 2015 Aug; 63(5):397-403. PubMed ID: 26121380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays.
    Murray DJ; Brosnahan WJ; Pennell B; Kapalanski D; Weiler JM; Olson J
    J Cardiothorac Vasc Anesth; 1997 Feb; 11(1):24-8. PubMed ID: 9058215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring and management of anticoagulation in children requiring extracorporeal circulation.
    Malviya S
    Semin Thromb Hemost; 1997; 23(6):563-7. PubMed ID: 9469631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.